-
Mashup Score: 22Long‐Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER‐OLE Study - 14 hour(s) ago
BackgroundThe phase 2 PIONEER‐HCM (Phase 2 Open‐label Pilot Study Evaluating Mavacamten in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction) stud…
Source: www.ahajournals.orgCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 10Validation of a Suprasystolic Cuff System for Static and Dynamic Representation of the Central Pressure Waveform - 16 hour(s) ago
BackgroundNoninvasive pulse waveform analysis is valuable for central cardiovascular assessment, yet controversies persist over its validity in peripheral measurements. Our objective was to compare…
Source: www.ahajournals.orgCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 0A Comparison of 5 Measures of Accelerated Biological Aging and Their Association With Incident Cardiovascular Disease: The CARDIA Study - 17 hour(s) ago
BackgroundAccelerated biological aging is an increasingly popular way to track the acceleration of biology over time that may not be captured by calendar time. Biological aging has been linked to e…
Source: www.ahajournals.orgCategories: General Medicine News, Cardiology News and JournTweet-
Accelerated biological aging is a way to track the acceleration of biology over time that may not be captured by calendar time. Learn about the association between biological aging and incident cardiovascular disease in different subgroups. #AHAJournals https://t.co/bCa3aBTUWX https://t.co/4VbhsTSwQu
-
-
Mashup Score: 4
BackgroundCardiac donation after circulatory death is a promising option to increase graft availability. Graft preservation with 30 minutes of hypothermic oxygenated perfusion (HOPE) before normoth…
Source: www.ahajournals.orgCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 19
Tricuspid valve disease is an often underrecognized clinical problem that is associated with significant morbidity and mortality. Unfortunately, patients will often present late in their disease cour
Source: www.ahajournals.orgCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 25
Unhealthy diets are a major impediment to achieving a healthier population in the United States. Although there is a relatively clear sense of what constitutes a healthy diet, most of the US populati
Source: www.ahajournals.orgCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 19Four-Dimensional Flow MRI in Adult Type Christmas Tree ALCAPA With High Cardiac Output - 4 day(s) ago
Correspondence to: Philip Haaf, MD, Department of Cardiology, University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland. Email For Sources of Funding and Disclosures, see page XXX. Correspondence to: Philip Haaf, MD, Department of Cardiology, University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland. Email philip. haaf@usb. ch © 2024 American Heart Association, Inc. Originally published April 26,
Source: www.ahajournals.orgCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 17
BACKGROUND: The FORZA trial (FFR or OCT Guidance to Revascularize Intermediate Coronary Stenosis Using Angioplasty) prospectively compared the use of fractional flow reserve (FFR) or optical coherenc
Source: www.ahajournals.orgCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 1
BackgroundBlood pressure (BP) trajectories from young adulthood through middle age are associated with cardiovascular risk. We examined the associations of hypertension risk factors with BP traject…
Source: www.ahajournals.orgCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 1Quantitative Benefit–Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial - 7 day(s) ago
BackgroundThe VOYAGER PAD (Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral R…
Source: www.ahajournals.orgCategories: General Medicine News, Cardiology News and JournTweet
The longest‐term study of mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) supports continued safety and effectiveness of mavacamten for over 3 years in obstructive HCM. #AHAJournals @MasriAhmadMD https://t.co/rhghPN2raO https://t.co/0IQG5Oe0K3